NASDAQ: NVCN
TSX: NVC
VANCOUVER, June 15, 2016 /PRNewswire/ - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVC) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 15, 2016 in Vancouver, B.C. (the “Meeting”).
At the Meeting, the shareholders of the Company (the “Shareholders”) set the number of directors at six and re-elected board members Alexei Marko, Paul Geyer, Dr. Jane Hsiao, Steven Rubin, Dr. William O’Neill, and Doug Janzen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
Alexei Marko | 47,248,704 | 99.91% | 41,555 | 0.09% |
Paul Geyer | 47,248,704 | 99.91% | 41,555 | 0.09% |
Dr. Jane Hsiao | 42,119,905 | 89.07% | 5,170,354 | 10.93% |
Steven Rubin | 42,119,905 | 89.07% | 5,170,354 | 10.93% |
Dr. William O’Neill | 44,255,199 | 93.58% | 3,035,060 | 6.42% |
Doug Janzen | 44,301,903 | 93.68% | 2,988,356 | 6.32% |
At the Meeting, the Shareholders also re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company (99.91% of votes cast in favour).
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products in development include the Tiara, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
